Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Ann Arbor, Boca Raton, Huntington Beach, and Rochester, United StatesSee the 4 sitesAlso in 2 other countries, 7 sites
- Trial code
- NCT05185843
- EU 2023-508815-22-00
- EudraCT 2021-003635-29
- U1111-1298-3302
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 24 people enrolled
- Started
- 25 Feb 2022
- Expected to end
- Jun 2027
- Type of study
- Interventional
- Treatments tested
- Olezarsen
- Record updated
- 12 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants with FCS (clinical or genetic diagnosis) currently on or previously treated with volanesorsen (ISIS 304801); o Study participants in countries where Waylivra® is commercially approved and available for participants should not be deprived of the treatment option with Waylivra®. Participation in this study for such participants will only be allowed when Waylivra® was discontinued due to AEs
- The following concomitant medications will be allowed if dosing regimen is expected to remain constant through the end of the study (occasional or intermittent use of over-the-counter (OTC) medications will be allowed at Investigator's discretion):; Statins, omega-3 fatty acids (prescription and OTC), fibrates, or other lipid-lowering medications. Participants taking OTC omega-3 fatty acids should make every effort to remain on the same brand through the end of the study; Antidiabetic medications; Oral anticoagulants (e.g., dabigatran, rivaroxaban, or apixaban, and warfarin with regular clinical monitoring); Tamoxifen, estrogens or progestins
Who cannot take part
- Treatment with another investigational drug (non-oligonucleotide), biological agent, or device within 4 weeks of Screening, or 5 half-lives of investigational agent, whichever is longer
- Concomitant medication/procedure restrictions:; Systemic corticosteroids or anabolic steroids within 6 weeks prior to Screening and during the study unless approved by the Sponsor Medical Monitor; Plasma apheresis within 4 weeks prior to Screening or planned during the study
Where in United States
Also in 2 other countries, 7 sites
- University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND)Ann Arbor, United States
- Excel Medical Clinical Trials, LLCBoca Raton, United States
- Diabetes/Lipid Management & Research CenterHuntington Beach, United States
- University of Rochester School of MedicineRochester, United States
About the trial
What the trial wants to find out
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known as AKCEA -APOCIII-LRX) in participants with FCS previously treated with volanesorsen.
The group in the trial
- OlezarsenTreatment being tested
Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 209 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen (ISIS 304801)
- Record updated
- 12 December 2025